Martin & Co. Inc. TN decreased its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL – Free Report) by 2.7% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 94,717 shares of the company’s stock after selling 2,662 shares during the period. Omnicell comprises approximately 1.8% of Martin & Co. Inc. TN’s holdings, making the stock its 14th largest position. Martin & Co. Inc. TN’s holdings in Omnicell were worth $6,978,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of OMCL. MetLife Investment Management LLC raised its holdings in Omnicell by 55.4% during the first quarter. MetLife Investment Management LLC now owns 23,169 shares of the company’s stock worth $3,000,000 after buying an additional 8,257 shares during the last quarter. Rhumbline Advisers raised its holdings in Omnicell by 6.4% during the first quarter. Rhumbline Advisers now owns 111,098 shares of the company’s stock worth $14,386,000 after buying an additional 6,657 shares during the last quarter. Great West Life Assurance Co. Can grew its stake in shares of Omnicell by 0.4% in the 1st quarter. Great West Life Assurance Co. Can now owns 37,956 shares of the company’s stock worth $5,036,000 after acquiring an additional 144 shares in the last quarter. Raymond James Trust N.A. grew its stake in shares of Omnicell by 10.9% in the 1st quarter. Raymond James Trust N.A. now owns 3,881 shares of the company’s stock worth $503,000 after acquiring an additional 382 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Omnicell by 0.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 848,688 shares of the company’s stock worth $109,901,000 after acquiring an additional 4,839 shares in the last quarter. Institutional investors and hedge funds own 99.18% of the company’s stock.
Analyst Ratings Changes
Several analysts have recently issued reports on OMCL shares. TheStreet lowered shares of Omnicell from a “c-” rating to a “d+” rating in a research note on Tuesday, October 24th. StockNews.com assumed coverage on shares of Omnicell in a research note on Thursday, October 5th. They issued a “hold” rating for the company. BTIG Research lowered shares of Omnicell from a “buy” rating to a “neutral” rating in a research report on Friday, November 3rd. Piper Sandler upgraded shares of Omnicell from a “neutral” rating to an “overweight” rating and reduced their price target for the company from $70.00 to $39.00 in a research report on Friday, November 3rd. Finally, Wells Fargo & Company upgraded shares of Omnicell from an “underweight” rating to an “equal weight” rating and reduced their price target for the company from $39.00 to $28.00 in a research report on Friday, November 3rd. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Omnicell currently has a consensus rating of “Hold” and a consensus target price of $53.00.
Omnicell Stock Performance
Shares of OMCL traded down $0.27 during trading hours on Monday, hitting $32.84. The company’s stock had a trading volume of 109,941 shares, compared to its average volume of 526,326. The company has a market cap of $1.49 billion, a price-to-earnings ratio of -43.00, a PEG ratio of 4.86 and a beta of 0.95. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.47 and a quick ratio of 2.16. The business has a 50 day simple moving average of $41.47 and a two-hundred day simple moving average of $58.18. Omnicell, Inc. has a 52-week low of $28.72 and a 52-week high of $77.14.
Omnicell Company Profile
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
- Five stocks we like better than Omnicell
- What Are Trending Stocks? Trending Stocks Explained
- Cisco stock plummets on weak forecast: Is it a warning for tech?
- What to Know About Investing in Penny Stocks
- An inside day for Target says another sell-off looms
- What is a Special Dividend?
- 2 stocks that under-promised and over-delivered on their earnings
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.